Epstein-Barr virus (EBV) is the representative of the family of Herpesviridae. Infectious mononucleosis is considered clinical form of primary human EBV infection after that the virus is retained in human organism during all life with the subsequent reactivation under influencing of different factors, both internal condition of an organism, and environment that results in clinical presentations of a miscellaneous degree of complication. EBV can be the agent to cause miscellaneous lymphomas such as nasopharyngeal carcinoma, carcinoma of parotid glands, stomach adenocarcinoma and other diseases. As well as other herpesviruses EBV affects central and peripheric nervous systems.
Summarize above it is possible to conclude that a modern arsenal of antiherpetic substances is rather miscellaneous. However, despite of it herpes as ARVI remains difficult controlled infection. It is caused as genetypical features of pathogen so and long-lived persistence of virus in organism and formation of resistant strains to antiviral drugs. Therefore search for new antiherpetics is still important. In the laboratory of viruses reproduction IMV of NASU drug screening of the miscellaneous nature with the purpose of detection of new substances with the expressed activity& against EBV is carried out permanently. Among developments of the Ukrainian chemists and pharmacists it is possible to mark out numbers of substances of miscellaneous nature, which have shown rather high anti-EBV activity and low cytotoxicity, that &was revealed in our investigations. There are drugs of nucleoside nature, such as 6-Azacitidin and its derivative, threecyclic nucleosides, iodine-contained drugs, such as Amizon and its derivative; drugs based on the plant extractions Proteflasid an&d Altabor. Antiviral activity of these investigated preparations and their new properties such as apoptosismodulatory were studied. That is the relevant feature outgoing from many-sided nature of EBV developments in clinical practice in particular it&s transforming capacity. Thus, the obtained data will allow creating new antiviral drugs based on such substances for control of human diseases caused by EBV
